SCHEMBL300386

SCHEMBL300386

CN(C)c1ccc(-c2cnc(-c3ccc(S(=O)(=O)NCCNC(=O)CBr)cc3)o2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.44
MMP2 P08253 3/20 0.43
MMP9 P14780 3/20 0.43
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA12 O43570 1/20 0.37
CA4 P22748 1/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
FLT3 P36888 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
NAMPT P43490 2/20 0.36
NPC1 O15118 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014512 0.85 HTR6 (0.44) HTR6MMP2MMP9CA1CA2
SCHEMBL6014557 0.84 HTR6 (0.42) HTR6MMP2MMP9CA1CA2
SCHEMBL6014405 0.83 HTR6 (0.48) HTR6MMP2MMP9CA1CA2
SCHEMBL700914 0.82 MMP2 (0.51) HTR6MMP2MMP9CA1CA2
SCHEMBL6014544 0.82 HTR6 (0.47) HTR6MMP2MMP9CA1CA2
SCHEMBL6014355 0.82 MMP9 (0.48) HTR6MMP2MMP9CA1CA2
SCHEMBL6014500 0.81 MMP2 (0.43) HTR6MMP2MMP9CA1CA2
SCHEMBL16267636 0.81 HTR6 (0.37) HTR6MMP2MMP9CA1CA2
SCHEMBL6014593 0.80 ALDH1A1 (0.39) HTR6MMP2MMP9MAPTFLT3
SCHEMBL6014472 0.79 MMP2 (0.47) HTR6MMP2MMP9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458760-B1 ENTRAPPED BINDING PROTEINS AS BIOSENSORS BECTON DICKINSON CO (US) 2012-03-07 EP claimed
US-7851593-B2 Binding proteins as biosensors BECTON, DICKINSON AND COMPANY (US) 2010-12-14 US claimed
US-20070281368-A1 BINDING PROTEINS AS BIOSENSORS HSIEH HELEN V 2007-12-06 US claimed
WO-2005080988-A1 BINDING PROTEINS AS BIOSENSORS BECTON, DICKINSON AND COMPANY (US) 2005-09-01 WO claimed
US-20050014290-A1 Binding proteins as biosensors BECTON, DICKINSON AND COMPANY 2005-01-20 US claimed
US-12569679-B2 Treatment delivery system WearOptimo Pty Ltd (AU) 2026-03-10 US disclosed
US-12487180-B2 Device and methods for quantifying analytes introduction Life Technologies Corporation (US) 2025-12-02 US disclosed
EP-4633458-A1 SYSTEMS AND METHODS FOR ANALYTE DETECTION Adaptyx Biosciences, Inc. (US) 2025-10-22 EP disclosed
US-20250120620-A1 SYSTEMS AND METHODS FOR ANALYTE DETECTION Adaptyx Biosciences, Inc. 2025-04-17 US disclosed
US-20250025078-A1 ELECTRODE ARRANGEMENT WearOptimo Pty Ltd (AU) 2025-01-23 US disclosed
US-12109019-B2 Systems and methods for analyte detection Adaptyx Biosciences, Inc. (US) 2024-10-08 US disclosed
WO-2024130117-A1 SYSTEMS AND METHODS FOR ANALYTE DETECTION Adaptyx Biosciences, Inc. (US) 2024-06-20 WO disclosed
WO-2006108095-A9 SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME UNIV MARYLAND (US) 2006-11-23 WO disclosed
WO-2006110748-A2 RESPONSE GENE TO COMPLEMENT 32 (RGC-32) IN DISEASE THE UNIVERSITY OF MARYLAND, BALTIMORE (US) 2006-10-19 WO disclosed
WO-2006108095-A2 SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME THE UNIVERSITY OF MARYLAND, BALTIMORE (US) 2006-10-12 WO disclosed
WO-2006063213-A2 SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2006-06-15 WO disclosed
WO-2006023635-A2 METHODS OF SCREENING PROTEINS BECTON, DICKINSON AND COMPANY (US) 2006-03-02 WO disclosed
US-20060040327-A1 Methods of screening proteins AMISS TERRY 2006-02-23 US disclosed
WO-2005080988-A1 BINDING PROTEINS AS BIOSENSORS BECTON, DICKINSON AND COMPANY (US) 2005-09-01 WO disclosed
US-20050014290-A1 Binding proteins as biosensors BECTON, DICKINSON AND COMPANY 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12569679-B2 Treatment delivery system PIEZO1, DSG1, KRT18 HTR6 9/4885MMP2 123/4885MMP9 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.